Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a2f7160a3604c7ab74567cee42b953c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a2f7160a3604c7ab74567cee42b953c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8a2f7160a3604c7ab74567cee42b953c2021-11-05T15:20:50ZPost-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells1664-322410.3389/fimmu.2021.753890https://doaj.org/article/8a2f7160a3604c7ab74567cee42b953c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.753890/fullhttps://doaj.org/toc/1664-3224Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which is impaired in heavily pre-treated HL patients. Here, we aimed to enhance the activity of early post-ASCT CI (nivolumab) administration with the infusion of autologous lymphocytes (ALI). Twelve patients with relapse/refractory (R/R) HL (median age 28.5 years; range 18-65), underwent lymphocyte apheresis after first line chemotherapy and then proceeded to salvage therapy. Subsequently, 9 patients with progressive disease at ASCT received early post-transplant CI supported with four ALI, whereas 3 responding patients received ALI alone, as a control cohort. No severe adverse events were recorded. HL-treated patients achieved negative PET scan CR and 8 are alive and disease-free after a median follow-up of 28 months. Four patients underwent subsequent allogeneic SCT. Phenotypic analysis of circulating cells showed a faster expansion of highly differentiated NK cells in ALI plus nivolumab-treated patients as compared to control patients. Our data show anti-tumor activity with good tolerability of ALI + CI for R/R HL and suggest that this setting may accelerate NK cell development/maturation and favor the expansion of the “adaptive” NK cell compartment in patients with HCMV seropositivity, in the absence of HCMV reactivation.Fabio GuoloFabio GuoloPaola MinettoSilvia PesceFilippo BalleriniMarino ClavioMichele CeaMichele CeaMichela FrelloMatteo GaribottoMarco GreppiMatteo BozzoMatteo BozzoMaurizio MiglinoMaurizio MiglinoMonica PassannanteRiccardo MarcolinElisabetta TedoneNicoletta ColomboRosa MangeriniAlessandra BoMaria Rosaria RuzzenentiPaolo CarlierAlberto SerioSilvia LuchettiAlida DominiettoRiccardo VaraldoSimona CandianiVanessa AgostiniJean Louis RavettiGenny Del ZottoEmanuela MarcenaroRoberto Massimo LemoliRoberto Massimo LemoliFrontiers Media S.A.articleHodgkin lymphomanivolumabnatural killer cellsprogrammed cell death receptor 1NK cell maturationimmune check pointImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Hodgkin lymphoma nivolumab natural killer cells programmed cell death receptor 1 NK cell maturation immune check point Immunologic diseases. Allergy RC581-607 |
| spellingShingle |
Hodgkin lymphoma nivolumab natural killer cells programmed cell death receptor 1 NK cell maturation immune check point Immunologic diseases. Allergy RC581-607 Fabio Guolo Fabio Guolo Paola Minetto Silvia Pesce Filippo Ballerini Marino Clavio Michele Cea Michele Cea Michela Frello Matteo Garibotto Marco Greppi Matteo Bozzo Matteo Bozzo Maurizio Miglino Maurizio Miglino Monica Passannante Riccardo Marcolin Elisabetta Tedone Nicoletta Colombo Rosa Mangerini Alessandra Bo Maria Rosaria Ruzzenenti Paolo Carlier Alberto Serio Silvia Luchetti Alida Dominietto Riccardo Varaldo Simona Candiani Vanessa Agostini Jean Louis Ravetti Genny Del Zotto Emanuela Marcenaro Roberto Massimo Lemoli Roberto Massimo Lemoli Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells |
| description |
Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which is impaired in heavily pre-treated HL patients. Here, we aimed to enhance the activity of early post-ASCT CI (nivolumab) administration with the infusion of autologous lymphocytes (ALI). Twelve patients with relapse/refractory (R/R) HL (median age 28.5 years; range 18-65), underwent lymphocyte apheresis after first line chemotherapy and then proceeded to salvage therapy. Subsequently, 9 patients with progressive disease at ASCT received early post-transplant CI supported with four ALI, whereas 3 responding patients received ALI alone, as a control cohort. No severe adverse events were recorded. HL-treated patients achieved negative PET scan CR and 8 are alive and disease-free after a median follow-up of 28 months. Four patients underwent subsequent allogeneic SCT. Phenotypic analysis of circulating cells showed a faster expansion of highly differentiated NK cells in ALI plus nivolumab-treated patients as compared to control patients. Our data show anti-tumor activity with good tolerability of ALI + CI for R/R HL and suggest that this setting may accelerate NK cell development/maturation and favor the expansion of the “adaptive” NK cell compartment in patients with HCMV seropositivity, in the absence of HCMV reactivation. |
| format |
article |
| author |
Fabio Guolo Fabio Guolo Paola Minetto Silvia Pesce Filippo Ballerini Marino Clavio Michele Cea Michele Cea Michela Frello Matteo Garibotto Marco Greppi Matteo Bozzo Matteo Bozzo Maurizio Miglino Maurizio Miglino Monica Passannante Riccardo Marcolin Elisabetta Tedone Nicoletta Colombo Rosa Mangerini Alessandra Bo Maria Rosaria Ruzzenenti Paolo Carlier Alberto Serio Silvia Luchetti Alida Dominietto Riccardo Varaldo Simona Candiani Vanessa Agostini Jean Louis Ravetti Genny Del Zotto Emanuela Marcenaro Roberto Massimo Lemoli Roberto Massimo Lemoli |
| author_facet |
Fabio Guolo Fabio Guolo Paola Minetto Silvia Pesce Filippo Ballerini Marino Clavio Michele Cea Michele Cea Michela Frello Matteo Garibotto Marco Greppi Matteo Bozzo Matteo Bozzo Maurizio Miglino Maurizio Miglino Monica Passannante Riccardo Marcolin Elisabetta Tedone Nicoletta Colombo Rosa Mangerini Alessandra Bo Maria Rosaria Ruzzenenti Paolo Carlier Alberto Serio Silvia Luchetti Alida Dominietto Riccardo Varaldo Simona Candiani Vanessa Agostini Jean Louis Ravetti Genny Del Zotto Emanuela Marcenaro Roberto Massimo Lemoli Roberto Massimo Lemoli |
| author_sort |
Fabio Guolo |
| title |
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells |
| title_short |
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells |
| title_full |
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells |
| title_fullStr |
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells |
| title_full_unstemmed |
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells |
| title_sort |
post-transplant nivolumab plus unselected autologous lymphocytes in refractory hodgkin lymphoma: a feasible and promising salvage therapy associated with expansion and maturation of nk cells |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/8a2f7160a3604c7ab74567cee42b953c |
| work_keys_str_mv |
AT fabioguolo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT fabioguolo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT paolaminetto posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT silviapesce posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT filippoballerini posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT marinoclavio posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT michelecea posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT michelecea posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT michelafrello posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT matteogaribotto posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT marcogreppi posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT matteobozzo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT matteobozzo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT mauriziomiglino posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT mauriziomiglino posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT monicapassannante posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT riccardomarcolin posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT elisabettatedone posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT nicolettacolombo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT rosamangerini posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT alessandrabo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT mariarosariaruzzenenti posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT paolocarlier posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT albertoserio posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT silvialuchetti posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT alidadominietto posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT riccardovaraldo posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT simonacandiani posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT vanessaagostini posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT jeanlouisravetti posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT gennydelzotto posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT emanuelamarcenaro posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT robertomassimolemoli posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells AT robertomassimolemoli posttransplantnivolumabplusunselectedautologouslymphocytesinrefractoryhodgkinlymphomaafeasibleandpromisingsalvagetherapyassociatedwithexpansionandmaturationofnkcells |
| _version_ |
1718444173352239104 |